<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Briasoulis, E.</style></author><author><style face="normal" font="default" size="100%">Samantas, E.</style></author><author><style face="normal" font="default" size="100%">Kalofonos, H.</style></author><author><style face="normal" font="default" size="100%">Skarlos, D.</style></author><author><style face="normal" font="default" size="100%">Makatsoris, T.</style></author><author><style face="normal" font="default" size="100%">Christodoulou, C.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Kosmidis, P.</style></author><author><style face="normal" font="default" size="100%">N. Pavlidis</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Chemotherapy and Pharmacology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cisplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Etoposide</style></keyword><keyword><style  face="normal" font="default" size="100%">Irinotecan</style></keyword><keyword><style  face="normal" font="default" size="100%">Phase I</style></keyword><keyword><style  face="normal" font="default" size="100%">Small-cell lung cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-27644521908&amp;doi=10.1007%2fs00280-004-0994-8&amp;partnerID=40&amp;md5=5dd21ff01a823760ff81c2d6dfa0537b</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">56</style></volume><pages><style face="normal" font="default" size="100%">521 - 528</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. Successive cohorts of AS-SCLC patients were treated with irinotecan administered as a single 1-h infusion in combination with fixed doses of cisplatin (20 mg/m 2) and etoposide (75 mg/m2), both given for three consecutive days (ECI regimen). Irinotecan dose was escalated from 60 mg/m 2 by 40-mg/m2 increments. At mid-step between the maximum tolerated dose (MTD) and the previous dose level, patients were randomized for the day of administration of irinotecan (day 1 vs day 3). A total of 36 AS-SCLC patients received 166 courses of treatment at four dose levels. The MTD of irinotecan was 140 mg/m2 (three dose-limiting toxicities, DLTs), and the recommended optimal dose (ROD) 120 mg/m2 (two DLTs). DLTs were febrile neutropenia and grade 3 diarrhea. Other toxicities were mild. No difference in toxicity was seen between the two time schedules. A 77% (95% CI 63.25-90.75%) response rate was recorded among 31 evaluable patients and the median survival was 12 months. The ECI regimen was well tolerated and showed considerable activity in patients with AS-SCLC. Phase II/III evaluation is ongoing. © Springer-Verlag 2005.</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><notes><style face="normal" font="default" size="100%">Cited By :4Export Date: 21 February 2017</style></notes></record></records></xml>